<span item_type="fundamental" item_id="7cc6b9d5919fb1e3f93f764f5e9001b2" counter_id="ST/US/BFRIW" env="prod"></span><span item_type="announcement" item_id="582319917329946497" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 6.988 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.62.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -6.167 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenues for the third quarter of 2025 were $7.0 million, a decrease from $9.0 million in the third quarter of 2024, reflecting a 22% year-over-year decline due to advanced purchases ahead of the October 2024 price increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Total revenues for the first nine months of 2025 were $24.6 million, slightly down from $24.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating expenses decreased by 5% year-over-year in the third quarter of 2025 compared to the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Cost of revenues decreased by $2.8 million, or 58%, compared to the three months ended September 30, 2024, primarily due to reduced Ameluz costs agreed upon with Biofrontera AG.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Selling, general, and administrative expenses were $10.4 million for the third quarter of 2025, up from $8.4 million in the third quarter of 2024, driven by increased legal costs due to patent claims.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Net loss for the third quarter of 2025 was $6.6 million, compared to a net loss of $5.7 million for the prior-year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>Adjusted EBITDA for the third quarter of 2025 was - $6.0 million compared to - $4.6 million for the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash balance was $3.4 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG included a new earnout structure reducing payment rates to 12%–15% of U.S. net sales from 25%–35%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Biofrontera Inc. anticipates substantial fourth quarter and year-over-year annual revenue growth, supported by growing demand for Ameluz-PDT treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The company is positioned for sustained growth and profitability due to a revamped commercial approach and recent transactions enhancing gross margins.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li><li>The acquisition of U.S. rights for Ameluz and RhodoLED lamps is expected to significantly enhance long-term profitability.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/ex99-1.htm"></span></li></ul>

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 6.988 M